Kepler Cheuvreux Suisse SA Invests $567,000 in Alnylam Pharmaceuticals, Inc. $ALNY

Kepler Cheuvreux Suisse SA acquired a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,713 shares of the biopharmaceutical company’s stock, valued at approximately $567,000.

Other hedge funds have also made changes to their positions in the company. MV Capital Management Inc. purchased a new stake in Alnylam Pharmaceuticals during the 4th quarter worth $25,000. HM Payson & Co. purchased a new position in Alnylam Pharmaceuticals in the fourth quarter valued at about $27,000. Golden State Wealth Management LLC raised its position in Alnylam Pharmaceuticals by 100.0% in the fourth quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 36 shares during the period. Caitong International Asset Management Co. Ltd acquired a new position in shares of Alnylam Pharmaceuticals during the third quarter worth about $29,000. Finally, Ameriflex Group Inc. acquired a new position in shares of Alnylam Pharmaceuticals during the third quarter worth about $32,000. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Price Performance

Shares of Alnylam Pharmaceuticals stock opened at $312.78 on Monday. The business has a 50-day moving average of $295.50 and a 200-day moving average of $327.86. The company has a debt-to-equity ratio of 0.94, a current ratio of 3.13 and a quick ratio of 3.06. The company has a market capitalization of $41.76 billion, a PE ratio of 85.46 and a beta of 0.27. Alnylam Pharmaceuticals, Inc. has a 1-year low of $273.11 and a 1-year high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 EPS for the quarter, topping the consensus estimate of $0.87 by $1.12. The business had revenue of $1.17 billion for the quarter, compared to analysts’ expectations of $1.12 billion. Alnylam Pharmaceuticals had a return on equity of 85.76% and a net margin of 11.72%.The company’s revenue was up 96.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.44) earnings per share. As a group, equities analysts forecast that Alnylam Pharmaceuticals, Inc. will post 7.36 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms have recently issued reports on ALNY. Chardan Capital reiterated a “buy” rating and issued a $425.00 target price on shares of Alnylam Pharmaceuticals in a research note on Wednesday, March 25th. Truist Financial reduced their price target on Alnylam Pharmaceuticals from $515.00 to $505.00 and set a “buy” rating on the stock in a research report on Monday, April 13th. Royal Bank Of Canada reduced their price target on Alnylam Pharmaceuticals from $450.00 to $445.00 and set an “outperform” rating on the stock in a research report on Friday, May 1st. Citigroup started coverage on Alnylam Pharmaceuticals in a report on Tuesday, May 19th. They issued a “buy” rating and a $380.00 price target for the company. Finally, Jefferies Financial Group reaffirmed a “hold” rating and issued a $330.00 price objective (down from $522.00) on shares of Alnylam Pharmaceuticals in a research report on Monday, March 16th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $461.39.

Insider Transactions at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, Director David E. I. Pyott sold 3,830 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the sale, the director directly owned 1,582 shares in the company, valued at $473,302.76. The trade was a 70.77% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.86% of the stock is owned by corporate insiders.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.